New mRNA flu shot enters human testing

NCT ID NCT05829356

Completed ⭐️ VACCINE ⭐️ Sponsor: Sanofi Pasteur, a Sanofi Company Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tests a new mRNA-based flu vaccine in 159 adults aged 18-49 and 60+. The vaccine uses modified mRNA to target a specific flu strain (H3N2). Researchers compare its safety and immune response to a standard flu shot. The goal is to gather data to improve future mRNA flu vaccines.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: modified mRNA flu vaccine (H3 mRNA/LNP)
What this could lead to: If successful, this could lead to a more effective and adaptable flu vaccine using mRNA technology.
What could go wrong: This is a very early Phase 1 trial with only 159 participants, so safety and immune response are still being tested. It may not work better than existing vaccines.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA IMMUNIZATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLUENZA IMMUNIZATION

Contacts and locations

Locations

Investigational Site Number : 0360001

Morayfield, Queensland, 4506, Australia
Investigational Site Number : 0360002

Camberwell, Victoria, 3124, Australia
Investigational Site Number : 0360003

Adelaide, 5000, Australia
Investigational Site Number : 0360004

Herston, Queensland, 4006, Australia
Investigational Site Number : 8260001

London, London, City of, SW10 9NH, United Kingdom
Investigational Site Number : 8260002

Leicester, Leicestershire, LE1 5WW, United Kingdom
Investigational Site Number : 8260003

Sheffield, Sheffield, S10 2JF, United Kingdom
Investigational Site Number : 8260004

London, London, City of, W12 0HS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.